Send the following on WhatsApp
Continue to Chathttps://forschung.kssg.ch/de/projects/1090-a-phase-3-randomized-double-blind-active-comparator-controlled-clinical-study-of-adjuvant-mk-7684a-vibostolimab-with-pembrolizumab-versus-adjuvant-pembrolizumab-in-participants-with-high-risk-stage-ii-iv-melanoma-keyvibe-010